telbivudin
oral
bioavail
lnucleosid
potent
specif
antihepat
b
viru
activ
higher
rate
hepat
b
e
antigen
hbeag
seroconvers
telbivudin
treatment
potent
antihbv
agent
suggest
potenti
immunomodulatori
effect
sought
determin
effect
telbivudin
immun
system
particularli
cytokin
product
tcell
respons
use
anim
model
mous
hepat
viru
strain
induc
hepat
effect
telbivudin
viru
replic
cytokin
product
investig
vitro
use
macrophag
effect
tcell
respons
investig
vivo
viral
hepat
model
telbivudin
effect
replic
macrophag
howev
product
tumour
necrosi
factora
increas
significantli
macrophag
treat
telbivudin
vivo
surviv
enhanc
telbivudinetr
mice
mark
normal
clinic
condit
histolog
lesion
serum
level
interferonc
elev
significantli
telbivudin
treatment
mice
contrast
serum
level
decreas
significantli
furthermor
telbivudin
treatment
enhanc
abil
cell
undergo
prolifer
secret
cytokin
affect
cytotox
infect
hepatocyt
note
found
telbivudin
treatment
suppress
program
death
ligand
express
cell
result
demonstr
immunomodulatori
properti
telbivudin
independ
antivir
activ
mous
model
hepat
keyword
hepat
b
viru
interleukin
oral
nucleo
ide
analogu
program
death
ligand
tumour
necrosi
factor
abbrevi
chb
chronic
hepat
b
fasl
fa
ligand
hbeag
hepat
b
e
antigen
hbv
hepat
b
viru
mous
hepat
viru
strain
program
death
program
death
ligand
hepat
b
viru
hbv
infect
signific
caus
liverrel
morbid
mortal
particularli
region
high
endem
natur
cours
clinic
outcom
hbv
infect
mediat
complex
interact
viru
immun
respons
success
control
hbv
replic
associ
strong
multispecif
tcell
respons
conjunct
humor
immun
respons
base
current
understand
hostviru
interact
natur
cours
hbv
infect
manag
strategi
focuss
enhanc
hbvspecif
tcell
respons
direct
suppress
hbv
replic
attain
sustain
viral
control
remiss
liver
diseas
current
avail
antihbv
therapi
interferon
ifn
pegyl
ifna
demonstr
immunomodulatori
effect
hbv
immunomodulatori
effect
report
nucleosid
ribavirin
mechan
action
consid
cell
differenti
upregul
activ
doublestrand
ds
rnaactiv
protein
kinas
littl
known
influenc
newer
oral
nucleosid
tcellspecif
immun
respons
telbivudin
lnucleosid
analogu
thymidin
potent
specif
inhibitor
hbv
dna
polymeras
approv
treatment
patient
chronic
hepat
b
chb
analysi
globe
studi
rate
hepat
b
e
antigen
hbeag
seroconvers
telbivudin
administr
higher
lamivudin
administr
patient
serum
alanin
aminotransferas
alt
level
greater
two
time
upper
limit
normal
uln
rel
high
hbeag
seroconvers
rate
attain
telbivudin
differ
rate
obtain
potent
antihbv
agent
suggest
telbivudin
potenti
immunomodulatori
activ
aim
present
studi
character
effect
telbivudin
cytokin
profil
tcell
respons
vitro
vivo
use
previous
character
mous
model
viral
hepat
induc
coronaviru
mous
hepat
viru
strain
effect
telbivudin
program
cell
death
pathway
possibl
mechan
tcell
function
influenc
also
investig
telbivudin
pure
substanc
obtain
novarti
pharma
basel
switzerland
lamivudin
purchas
moravek
biochem
brea
ca
usa
substanc
concentr
determin
highperform
liquid
chromatographi
mous
hepat
viru
strain
origin
obtain
american
type
cultur
collect
rockvil
md
usa
plaqu
purifi
monolay
dbt
cell
grown
titr
plaqueform
unit
pfu
ml
viru
harvest
centrifug
g
h
assay
monolay
cell
standard
plaqu
assay
femal
balbcj
mice
week
age
obtain
hubei
provinci
institut
scienc
technolog
wuhan
china
vital
river
compani
beij
china
respect
anim
studi
conduct
accord
chines
council
anim
care
approv
tongji
hospit
tongji
medic
colleg
huazhong
univers
scienc
technolog
wuhan
china
macrophag
isol
periton
macrophag
harvest
balbcj
mice
day
intraperiton
inject
ml
thioglycol
outlin
previous
macrophag
pure
determin
morpholog
viabil
exceed
trypan
blue
exclus
macrophag
incub
presenc
indic
concentr
telbivudin
lgml
macrophag
harvest
h
infect
viral
titr
determin
standard
plaqu
assay
cytokin
level
measur
pcr
enzymelink
immunosorb
assay
determin
effect
telbivudin
tumour
necrosi
factor
tnf
interleukin
il
cytokin
product
one
million
macrophag
balbcj
mice
stimul
multipl
infect
telbivudin
ad
indic
concentr
rel
quantit
realtim
polymeras
chain
reaction
pcr
perform
measur
mrna
level
roch
lightcycl
roch
diagnost
nutley
nj
usa
follow
instruct
cytokin
protein
level
determin
cell
supernat
follow
appropri
dilut
use
enzymelink
immunosorb
assay
elisa
r
system
abingdon
uk
cytokin
level
lipopolysaccharid
lp
stimul
macrophag
without
telbivudin
ad
strain
mice
also
investig
vivo
studi
anim
model
fifteen
mice
infect
pfu
receiv
telbivudin
mgkg
phosphatebuff
salin
pb
via
intraperiton
inject
day
start
h
infect
daili
thereaft
addit
mice
group
receiv
lamivudin
mgkg
per
day
pb
control
clinic
condit
surviv
observ
anim
kill
day
infect
spleen
liver
blood
collect
experi
effect
treatment
telbivudin
liver
diseas
determin
monitor
mice
twice
daili
chang
clinic
sign
includ
abnorm
fur
textur
increas
respir
presenc
tremor
condit
grade
scale
indic
mark
presenc
abnorm
indic
normalci
composit
score
paramet
calcul
two
independ
examin
blind
treatment
regimen
minim
bia
time
mice
kill
liver
remov
weigh
fix
buffer
formalin
minimum
h
tissu
process
paraffin
embed
routin
method
stain
haematoxylin
eosin
spleen
group
mice
harvest
day
infect
spleen
dissect
singlecel
suspens
made
passag
nylon
cell
strainer
densiti
gradient
centrifug
lysi
red
cell
ammonium
chlorid
solut
cell
prepar
studi
cell
purifi
singlecel
splenocyt
suspens
use
isol
kit
miltenyi
biotec
bergisch
gladbach
germani
mous
hepat
viru
strain
mice
anaesthet
liver
perfus
situ
ca
balanc
salt
solut
contain
mm
ethylenediaminetetraacet
acid
min
follow
collagenas
solut
type
iv
sigmaaldrich
st
loui
mo
usa
min
digest
liver
remov
place
steril
petri
dish
singlecel
suspens
prepar
viabil
hepatocyt
treatment
assess
trypan
blue
stain
day
mice
kill
sera
collect
assay
ifnc
use
appropri
elisa
r
system
mice
sacrif
indic
time
point
purifi
cell
cultur
cellsml
presenc
ngml
phorbol
myrist
acet
plu
lgml
ionomycin
h
plate
cell
stain
monoclon
antibodi
specif
surfac
marker
permeabil
fix
use
bd
franklin
lake
nj
usa
accord
instruct
differ
cell
subset
identifi
use
antibodi
ifnc
tnfa
perforin
granzym
b
ebiosci
san
diego
ca
usa
isotyp
antibodi
use
stain
apc
fluorescein
isothiocyan
fitc
antiprogram
death
antiprogram
death
ligand
antifa
ligand
fasl
antiperforin
antigranzym
b
antitnfa
antiifnc
pe
isotyp
control
pe
ebiosci
analys
perform
cell
sorter
bd
subsequ
analysi
perform
facsdiva
softwar
bd
freshli
isol
hepatocyt
mice
use
target
cell
cell
effector
cell
cytolyt
activ
determin
cytotox
nonradioact
cytotox
assay
promega
madison
wi
usa
effector
target
cell
ratio
rang
specif
target
cell
lysi
calcul
follow
experiment
releas
spontan
releas
maximum
releas
spontan
releas
effector
target
cell
ratio
measur
quadrupl
statist
analysi
conduct
ttest
pvalu
consid
statist
signific
result
report
mean
standard
deviat
three
separ
experi
perform
triplic
first
investig
whether
telbivudin
cytotox
effect
macrophag
addit
lgml
telbivudin
periton
macrophag
freshli
isol
balbcj
mice
toxic
effect
demonstr
trypan
blue
exclus
viabl
cell
examin
efficaci
telbivudin
viral
replic
directli
isol
macrophag
treat
telbivudin
indic
concentr
start
concentr
lgml
chosen
base
maxim
concentr
area
concentrationtim
curv
zero
infin
close
twice
dose
patient
administr
telbivudin
effect
replic
start
dose
lgml
dose
high
lgml
fig
experi
perform
test
abil
telbivudin
modul
immun
respons
macrophag
macrophag
produc
significantli
higher
level
tnfa
respons
infect
comparison
basal
valu
telbivudin
significantli
enhanc
product
tnfa
macrophag
compar
control
effect
occur
dosedepend
manner
fig
similar
pattern
increas
tnfa
mrna
product
also
observ
respons
telbivudin
fig
c
howev
telbivudin
effect
tnfa
level
mrna
product
lpsstimul
macrophag
fig
b
telbivudin
improv
surviv
clinic
outcom
vivo
telbivudin
increas
surviv
rate
mice
compar
pbstreat
control
fig
composit
clinic
score
obtain
combin
clinic
score
measur
symptom
telbivudinetr
mice
maintain
improv
composit
clinic
score
condit
categori
end
studi
fig
addit
improv
overal
surviv
clinic
score
telbivudin
reduc
histolog
sign
associ
infect
fig
liver
recov
pbstreat
mice
show
remark
necrosi
day
infect
compar
liver
obtain
uninfect
control
mice
arrow
fig
indic
necrosi
contrast
although
complet
free
diseas
liver
recov
telbivudinetr
mice
show
mark
reduct
histolog
evid
hepat
necrosi
fig
telbivudin
treatment
result
addit
increas
ifnc
product
sera
compar
control
tabl
contrast
inhibit
product
observ
telbivudinetr
group
compar
control
telbivudin
increas
total
number
cell
percentag
ifncand
tnfaproduc
cell
percentag
ifncproduc
cell
phenotyp
analysi
spleen
cell
telbivudinetr
mice
reveal
increas
total
number
cell
compar
pbsand
lamivudinetr
control
fig
frequenc
ifncproduc
cell
telbivudinetr
group
significantli
increas
compar
pbsand
lamivudinetr
group
fig
c
f
frequenc
tnfaproduc
cell
telbivudinetr
group
increas
significantli
compar
pbsand
lamivudin
treat
group
fig
g
frequenc
tnfaproduc
cell
similar
among
treatment
group
fig
g
differ
observ
frequenc
cell
data
shown
telbivudin
effect
cytolyt
function
downregul
express
cell
determin
whether
telbivudin
treatment
enhanc
killer
tcell
cytotox
perform
cytotox
assay
use
spleenisol
cell
effector
cell
increas
cytotox
fig
observ
infect
group
differ
observ
among
group
without
telbivudin
treatment
suggest
telbivudin
effect
cytolyt
function
cell
fasl
express
increas
infect
group
compar
uninfect
group
differ
observ
among
infect
group
fig
signific
differ
tumour
necrosi
factor
receptor
tnfr
perforin
granzym
b
express
cell
among
infect
group
uninfect
group
fig
understand
phenomenon
investig
express
found
telbivudin
treatment
significantli
downregul
express
cell
compar
pb
lamivudin
treatment
fig
e
first
studi
demonstr
vitro
vivo
telbivudin
immunomodulatori
effect
independ
potent
antivir
activ
data
show
telbivudin
inhibitori
effect
replic
macrophag
find
consist
fact
telbivudin
highli
select
hbv
lack
activ
virus
studi
show
telbivudin
concentr
achiev
vivo
enhanc
product
tnfa
balbcj
macrophag
vitro
challeng
telbivudin
unabl
caus
similar
effect
lpsinduc
inflammatori
cytokin
may
mechan
induct
tnfa
lp
differ
viru
previou
studi
immun
respons
antivir
treatment
nucleosid
nucleotid
analogu
patient
chb
shown
potent
suppress
hbv
replic
associ
enhanc
tcell
reactiv
cytokin
product
howev
studi
patient
chb
allow
dissect
whether
effect
adapt
immun
due
direct
immunomodulatori
properti
antivir
agent
secondari
reduc
viraemia
antigen
level
advantag
mous
model
allow
investig
potenti
immunomodulatori
effect
independ
antivir
activ
use
produc
straindepend
pattern
viral
hepat
inbr
strain
mice
brought
insight
pathogenesi
viral
hepat
previou
studi
use
virusinduc
hepat
model
group
show
ribavirin
preserv
cytokin
product
inhibit
cytokin
respons
studi
explor
remark
increas
sustain
virolog
respons
post
interferon
ribavirin
combin
therapi
hepat
c
patient
result
vitro
experi
macrophag
support
investig
immunomodulatori
effect
telbivudin
vivo
belong
coronaviru
famili
positivestrand
rna
virus
suitabl
model
studi
pure
immunomodulatori
effect
telbivudin
without
influenc
viral
inhibitori
effect
turn
may
indirectli
affect
immun
system
studi
telbivudin
treatment
significantli
improv
surviv
mice
improv
clinic
condit
histolog
outcom
treatment
mice
telbivudin
result
inhibit
product
similar
dose
telbivudin
enhanc
product
ifnc
furthermor
increas
total
cell
number
ifncproduc
cell
tnfaproduc
cell
indic
predominantli
respons
post
telbivudin
treatment
one
mechan
immun
respons
involv
naiv
cell
product
cytokin
control
develop
immuneeffector
mechan
concentr
ifnc
measur
sera
mice
day
infect
data
present
mean
sd
three
separ
experi
three
mice
group
p
compar
pbstreat
mice
respons
associ
host
resist
wherea
respons
associ
suscept
murin
model
studi
suggest
resist
associ
predomin
respons
product
ifn
cytotox
cell
cytotox
lymphocyt
kill
target
cell
two
major
pathway
one
depend
exocytosi
granul
effector
molecul
includ
perforin
granzym
b
depend
engag
target
cell
famili
death
receptor
eg
fa
effector
cellexpress
fasl
membranebound
secret
tnf
tnfrelat
apoptosisinduc
ligand
result
demonstr
fasl
play
import
role
cytotox
lymphocyt
ctl
cytotox
hepatocyt
mice
howev
telbivudin
treatment
promot
ctl
cytotox
previou
studi
establish
tnfa
ifnc
key
cytokin
noncytolyt
control
hbv
replic
releas
cytokin
cell
lead
inactiv
hbv
without
kill
infect
hepatocyt
result
suggest
telbivudin
alter
balanc
cytokin
independ
direct
antivir
effect
program
receptor
express
subset
activ
b
cell
also
known
express
haematopoiet
parenchym
cell
chronic
viral
infect
cell
express
high
level
ligand
also
highli
upregul
vivo
blockad
interact
ligand
report
enhanc
tcell
respons
reduct
treatment
chb
shown
correl
reduct
hbv
dna
level
given
role
import
inhibitori
pathway
tcell
function
effect
telbivudin
express
investig
defin
effect
telbivudin
tcell
respons
although
telbivudin
alter
express
note
significantli
downregul
express
cell
mice
result
provid
initi
evid
role
telbivudin
inhibitori
pathway
regul
tcell
function
may
favour
develop
immun
clearanc
viru
infect
howev
effect
telbivudin
express
cell
type
clarifi
studi
also
underli
molecular
mechan
requir
investig
one
propos
mechan
upregul
activ
cellular
kinas
facilit
effici
phosphoryl
hand
mani
nucleosid
analoguelik
substanc
eg
cpgcontain
dna
found
dna
virus
bacteria
viral
dsrna
viral
mimic
polyinosin
polycytidyl
acid
polyi
c
exert
immunomodulatori
activ
via
tolllik
receptor
telbivudin
thymidin
nucleosid
analogu
may
exert
immunomodulatori
activ
via
tolllik
receptor
summari
present
studi
demonstr
benefici
effect
telbivudin
hepat
may
mediat
effect
immun
respons
rather
inhibit
viral
replic
anim
model
immunomodulatori
effect
telbivudin
may
explain
partli
shift
balanc
immun
respons
turn
may
explain
benefit
telbivudin
amelior
infect
increas
surviv
well
improv
clinic
score
liver
histolog
data
identifi
immunomodulatori
mechan
telbivudin
treatment
viral
hepat
model
provid
insight
potenti
addit
mode
action
manag
viral
hepat
infect
